Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Subjects:	atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors
Online Access:	https://doi.org/10.1186/s12885-025-14400-9